AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20521029 — intervention group
Group type: COMPARATOR
Intervention: Current internalizing and externalizing symptoms
Number of subjects: 55
Study 19274317 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly doses of 25 mg of elemental iron administered at home
Number of subjects: 130
Study 19274317 — intervention group
Group type: COMPARATOR
Intervention: Weekly doses of 25 mg of elemental iron administered in healthcare clinic
Number of subjects: 130
Study 16996948 — intervention group
Group type: EXPERIMENTAL
Intervention: OPCAB
Number of subjects: 100
Study 16996948 — intervention group
Group type: COMPARATOR
Intervention: ONCAB
Number of subjects: 100
Study 16996948 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 14535968 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycaemia (15 mmol L(‐1))
Number of subjects: 18
Study 11094802 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamming clustering (HC)
Number of subjects: 115
Study 11094802 — intervention group
Group type: COMPARATOR
Intervention: Standard classifiers
Number of subjects: 115
Study 2029860 — intervention group
Group type: COMPARATOR
Intervention: Tramadol 75 mg
Number of subjects: 0
Study 2029860 — intervention group
Group type: COMPARATOR
Intervention: Tramadol 150 mg
Number of subjects: 0
Study 2029860 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 300 mg
Number of subjects: 0
Study 2029860 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 15 mg
Number of subjects: 0
Study 2029860 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 30 mg
Number of subjects: 0
Study 2029860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7204788 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine
Number of subjects: 7
Study 7204788 — intervention group
Group type: EXPERIMENTAL
Intervention: Ragweed
Number of subjects: 7
Study 30865796 — intervention group
Group type: EXPERIMENTAL
Intervention: Bempedoic acid
Number of subjects: 2230
Study 30865796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2230
Study 28803797 — intervention group
Group type: COMPARATOR
Intervention: Hot conditions (35°C/40%rH)
Number of subjects: 10
Study 28803797 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperate conditions (24°C/30%rH)
Number of subjects: 10
Study 27812636 — intervention group
Group type: EXPERIMENTAL
Intervention: Gel pillow with side cutouts
Number of subjects: 23
Study 27812636 — intervention group
Group type: COMPARATOR
Intervention: Control pillow (own pillow)
Number of subjects: 23
Study 27812636 — intervention group
Group type: COMPARATOR
Intervention: Foam pillow
Number of subjects: 23
Study 24440576 — intervention group
Group type: EXPERIMENTAL
Intervention: Attempts to control worry
Number of subjects: 0
Study 24440576 — intervention group
Group type: COMPARATOR
Intervention: Attempts to control neutral thought
Number of subjects: 0
Study 24440576 — intervention group
Group type: COMPARATOR
Intervention: Subset of participants without instructions to control thoughts
Number of subjects: 0
Study 22149291 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental contrasting
Number of subjects: 134
Study 22149291 — intervention group
Group type: COMPARATOR
Intervention: Indulging
Number of subjects: 134
Study 22149291 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 134
Study 20399363 — intervention group
Group type: EXPERIMENTAL
Intervention: Reamed intramedullary nailing
Number of subjects: 0
Study 20399363 — intervention group
Group type: COMPARATOR
Intervention: Unreamed intramedullary nailing
Number of subjects: 0
Study 17379047 — intervention group
Group type: EXPERIMENTAL
Intervention: VAL/HCTZ 320/25 mg
Number of subjects: 1346
Study 17379047 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1346
Study 17379047 — intervention group
Group type: COMPARATOR
Intervention: HCTZ monotherapies
Number of subjects: 1346
Study 17379047 — intervention group
Group type: EXPERIMENTAL
Intervention: VAL/HCTZ combinations
Number of subjects: 1346
Study 16270637 — intervention group
Group type: EXPERIMENTAL
Intervention: Ximelagatran 24 mg twice daily
Number of subjects: 1223
Study 16270637 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1223
Study 11888606 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomised participants
Number of subjects: 0
Study 11888606 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary analyses (per-protocol or as-treated participants)
Number of subjects: 0
Study 10190880 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing position
Number of subjects: 13
Study 10190880 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyramine administration
Number of subjects: 13
Study 10190880 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol administration
Number of subjects: 13
Study 10190880 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine administration
Number of subjects: 13
Study 10190880 — intervention group
Group type: EXPERIMENTAL
Intervention: Baroreflex sensitivity measurement
Number of subjects: 13
Study 10190880 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrinsic heart rate measurement
Number of subjects: 13
Study 7800313 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous electronic fetal heart rate monitoring (EFM)
Number of subjects: 18561
Study 11527135 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg)
Number of subjects: 40
Study 11527135 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol (5 mg)
Number of subjects: 40
Study 11527135 — intervention group
Group type: COMPARATOR
Intervention: Atenolol and Bisoprolol (both beta1-selective beta-blockers)
Number of subjects: 40
Study 6127907 — intervention group
Group type: EXPERIMENTAL
Intervention: Clorazepate
Number of subjects: 127
Study 6127907 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-anxiety drugs (including clorazepate and diazepam)
Number of subjects: 127
Study 6127907 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 6127907 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam plus bendrofluazide
Number of subjects: 127
Study 6127907 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendrofluazide
Number of subjects: 127
Study 6127907 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 127
Study 31500444 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator implantation
Number of subjects: 1116
Study 31500444 — intervention group
Group type: COMPARATOR
Intervention: Control group (no implantable cardioverter-defibrillator implantation)
Number of subjects: 1116
Study 30588277 — intervention group
Group type: EXPERIMENTAL
Intervention: Telerehabilitation (TR) treatment
Number of subjects: 0
Study 30588277 — intervention group
Group type: COMPARATOR
Intervention: In-person (IP) treatment
Number of subjects: 0
Study 27771799 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (1000 µg)
Number of subjects: 7
Study 27771799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 24253140 — intervention group
Group type: COMPARATOR
Intervention: 6% hydroxyethyl starch in 0.9% saline (Voluven)
Number of subjects: 12
Study 24253140 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced solution of 6% hydroxyethyl starch (Plasma Volume Redibag)
Number of subjects: 12
Study 21818062 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental initiation and standard 2.0 maintenance BPSPs (EXP-STD group)
Number of subjects: 105
Study 21818062 — intervention group
Group type: COMPARATOR
Intervention: Standard BPSPs (not explicitly named)
Number of subjects: 105
Study 20362992 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal-psychotherapy-oriented childbirth psychoeducation programme (2 x 90-min classes + telephone follow-up)
Number of subjects: 194
Study 20362992 — intervention group
Group type: COMPARATOR
Intervention: Routine childbirth education (control group)
Number of subjects: 194
Study 18630544 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and Moxibustion
Number of subjects: 686
Study 15704613 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of 20 mg rabeprazole
Number of subjects: 28
Study 15704613 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of 20 mg rabeprazole
Number of subjects: 28
Study 15704613 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (oral and intravenous)
Number of subjects: 28
Study 12915378 — intervention group
Group type: EXPERIMENTAL
Intervention: miniCEX rating scale (9-point scale)
Number of subjects: 40
Study 10329814 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG)
Number of subjects: 38
Study 10329814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 7795397 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25 mg)
Number of subjects: 40
Study 7795397 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 1780994 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine phosphate 2500 mg over 3 days
Number of subjects: 0
Study 1780994 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine prophylaxis 500 mg weekly for 27 weeks
Number of subjects: 0
Study 1780994 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine prophylaxis 500 mg weekly for 27 weeks after nodulectomy and acute malaria treatment
Number of subjects: 0
Study 1780994 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical and chemotherapeutic treatment
Number of subjects: 0
Study 7026074 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin‐vincristine (AV)
Number of subjects: 268
Study 7026074 — intervention group
Group type: EXPERIMENTAL
Intervention: AV plus dibromodulcitol (AVD)
Number of subjects: 268
Study 7026074 — intervention group
Group type: EXPERIMENTAL
Intervention: AV plus ICRF-159 (AVI)
Number of subjects: 268
Study 31926827 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist luteal support 0.1 mg SC every other day, starting on day 3 post egg retrieval
Number of subjects: 0
Study 31926827 — intervention group
Group type: COMPARATOR
Intervention: 80 Âµg recombinant hCG (Ovitrelle, Merck Serono SA) as control, single dose on day 3 post-egg retrieval
Number of subjects: 0
Study 31604069 — intervention group
Group type: EXPERIMENTAL
Intervention: High power condition
Number of subjects: 55
Study 31604069 — intervention group
Group type: EXPERIMENTAL
Intervention: Low power condition
Number of subjects: 55
Study 31604069 — intervention group
Group type: EXPERIMENTAL
Intervention: General positive emotion condition
Number of subjects: 55
Study 28120559 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound (IVUS)‐guided PCI
Number of subjects: 666
Study 25899956 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg orally twice a day for 4 days (10 doses total)
Number of subjects: 114
Study 25899956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study 25899956 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 114
Study 24306214 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal protein diet (NPD) - 1.2 g protein ⋅ kg body weight(‐1) ⋅ d(‐1)
Number of subjects: 20
Study 24306214 — intervention group
Group type: COMPARATOR
Intervention: Low protein diet (LPD) - 0.1 g protein ⋅ kg body weight(‐1) ⋅ d(‐1)
Number of subjects: 20
Study 23172127 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal quality improvement intervention
Number of subjects: 22
Study 23172127 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 22
Study 19763530 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive peripheral magnetic stimulation (RPMS) applied over the first sacral radix, 10 series of 10 seconds duration, frequency of 20 Hz, 1.2-fold intensity above motoric threshold
Number of subjects: 53
Study 19763530 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 53
Study 17823424 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid
Number of subjects: 732
Study 17823424 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (400-800 microg/d)
Number of subjects: 732
Study 17823424 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (5000 microg/d)
Number of subjects: 732
Study 17823424 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (10,000 microg/d)
Number of subjects: 732
Study 17823424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 732
Study 15172273 — intervention group
Group type: EXPERIMENTAL
Intervention: En bloc isolation of pulmonary veins
Number of subjects: 30
Study 15172273 — intervention group
Group type: EXPERIMENTAL
Intervention: Maze procedure
Number of subjects: 30
Study 15172273 — intervention group
Group type: COMPARATOR
Intervention: Mitral valve correction alone
Number of subjects: 30
Study 11524347 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib Sodium 20 mg IV
Number of subjects: 0
Study 11524347 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib Sodium 40 mg IV
Number of subjects: 0
Study 11524347 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib Sodium 80 mg IV
Number of subjects: 0
Study 11524347 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9930595 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine (10 mg daily p.o.)
Number of subjects: 10
Study 9930595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 9930595 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine
Number of subjects: 10
Study 8039123 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular ice pack therapy
Number of subjects: 62
Study 3051876 — intervention group
Group type: EXPERIMENTAL
Intervention: Nova-T
Number of subjects: 600
Study 3051876 — intervention group
Group type: EXPERIMENTAL
Intervention: MLCu375
Number of subjects: 600
Study 3051876 — intervention group
Group type: EXPERIMENTAL
Intervention: MLCu250
Number of subjects: 600
Study 4879883 — intervention group
Group type: EXPERIMENTAL
Intervention: tetracycline plus nystatin (Mysteclin)
Number of subjects: 111
Study 4879883 — intervention group
Group type: COMPARATOR
Intervention: tetracycline
Number of subjects: 111
Study 29016538 — intervention group
Group type: EXPERIMENTAL
Intervention: Healing time of 15.8 days
Number of subjects: 219
Study 29016538 — intervention group
Group type: EXPERIMENTAL
Intervention: Epithelialization time
Number of subjects: 219
Study 28291957 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal insulin (40IU)
Number of subjects: 19
Study 26184311 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid feed intake
Number of subjects: 528
Study 26184311 — intervention group
Group type: COMPARATOR
Intervention: Milk replacer (control)
Number of subjects: 528
Study 23345639 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 150 to 600 mg/d
Number of subjects: 108
Study 23345639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 21889769 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with statins and fenofibric acid (FA)
Number of subjects: 2228
Study 18066566 — intervention group
Group type: EXPERIMENTAL
Intervention: RAL (60 mg daily and continuously)
Number of subjects: 53
Study 18066566 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT (2 mg estradiol valerat + 2 mg dienogest, continuously)
Number of subjects: 53
Study 18066566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 15903364 — intervention group
Group type: EXPERIMENTAL
Intervention: Coreshorts compression shorts
Number of subjects: 13
Study 15903364 — intervention group
Group type: COMPARATOR
Intervention: No compression shorts (control)
Number of subjects: 13
Study 12780945 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirospec
Number of subjects: 45
Study 12780945 — intervention group
Group type: COMPARATOR
Intervention: Masterlab 4.0
Number of subjects: 45
Study 10645754 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 11008
Study 10645754 — intervention group
Group type: COMPARATOR
Intervention: NSAIDs
Number of subjects: 11008
Study 10645754 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11008
Study 10645754 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (subset with sulfonamide hypersensitivity)
Number of subjects: 11008
Study 10645754 — intervention group
Group type: COMPARATOR
Intervention: NSAIDs (subset with sulfonamide hypersensitivity)
Number of subjects: 11008
Study 10645754 — intervention group
Group type: COMPARATOR
Intervention: Placebo (subset with sulfonamide hypersensitivity)
Number of subjects: 11008
Study 8882114 — intervention group
Group type: EXPERIMENTAL
Intervention: Respirators without a particle filter
Number of subjects: 19
Study 8882114 — intervention group
Group type: COMPARATOR
Intervention: Respirators with a particle filter
Number of subjects: 19
Study 1993961 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic surfactant (Exosurf Neonatal) 5 ml/kg
Number of subjects: 446
Study 1993961 — intervention group
Group type: COMPARATOR
Intervention: Air (control group) 5 ml/kg
Number of subjects: 446
Study 6501237 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg yohimbine hydrochloride
Number of subjects: 10
Study 6501237 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg yohimbine hydrochloride
Number of subjects: 10
Study 6501237 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31132570 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrinsic state motivation
Number of subjects: 105
Study 31132570 — intervention group
Group type: EXPERIMENTAL
Intervention: State success motivation
Number of subjects: 105
Study 29720119 — intervention group
Group type: EXPERIMENTAL
Intervention: Baby boomers and post baby boomers
Number of subjects: 1069
Study 29720119 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiving without choice and longer hours on caregiving tasks
Number of subjects: 1069
Study 29720119 — intervention group
Group type: EXPERIMENTAL
Intervention: Post baby boomer caregivers
Number of subjects: 1069
Study 27055606 — intervention group
Group type: EXPERIMENTAL
Intervention: Jet injection of lidocaine
Number of subjects: 44
Study 27055606 — intervention group
Group type: COMPARATOR
Intervention: Needle infiltration of lidocaine
Number of subjects: 44
Study 24645800 — intervention group
Group type: EXPERIMENTAL
Intervention: Multitarget stool DNA test
Number of subjects: 9989
Study 24645800 — intervention group
Group type: COMPARATOR
Intervention: Fecal immunochemical test (FIT)
Number of subjects: 9989
Study 24645800 — intervention group
Group type: COMPARATOR
Intervention: Colonoscopy
Number of subjects: 9989
Study 22503057 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stent (BMS)
Number of subjects: 150
Study 22503057 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting balloon (DEB) plus bare-metal stent (BMS)
Number of subjects: 150
Study 22503057 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stent (DES)
Number of subjects: 150
Study 20159134 — intervention group
Group type: EXPERIMENTAL
Intervention: Painful shoulders (n=10)
Number of subjects: 26
Study 20159134 — intervention group
Group type: COMPARATOR
Intervention: Asymptomatic shoulders (n=16)
Number of subjects: 26
Study 17587750 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 0
Study 17587750 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 0
Study 14532938 — intervention group
Group type: COMPARATOR
Intervention: Thrombolysis in a community hospital (group A, n=99)
Number of subjects: 300
Study 14532938 — intervention group
Group type: COMPARATOR
Intervention: Thrombolysis during immediate transportation for coronary angioplasty (group B, n=100)
Number of subjects: 300
Study 14532938 — intervention group
Group type: COMPARATOR
Intervention: Immediate transportation for coronary angioplasty without thrombolysis (group C, n=101)
Number of subjects: 300
Study 11115952 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducative intervention (experimental group)
Number of subjects: 116
Study 11115952 — intervention group
Group type: COMPARATOR
Intervention: Usual medical follow-up (control group)
Number of subjects: 116
Study 11115952 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence >/=95%
Number of subjects: 116
Study 11115952 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducative intervention
Number of subjects: 116
Study 11115952 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor effort to take medication
Number of subjects: 116
Study 11115952 — intervention group
Group type: EXPERIMENTAL
Intervention: High self-perceived capacity to follow the regimen
Number of subjects: 116
Study 8941069 — intervention group
Group type: EXPERIMENTAL
Intervention: Sperm deformity index assessment
Number of subjects: 158
Study 8941069 — intervention group
Group type: EXPERIMENTAL
Intervention: Sperm deformity index
Number of subjects: 158
Study 8941069 — intervention group
Group type: COMPARATOR
Intervention: Proportion of normal sperm morphology
Number of subjects: 158
Study 8941069 — intervention group
Group type: EXPERIMENTAL
Intervention: Area under the ROC curve for sperm deformity index
Number of subjects: 158
Study 8941069 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy outcome
Number of subjects: 158
Study 14628738 — intervention group
Group type: EXPERIMENTAL
Intervention: HTK solution
Number of subjects: 0
Study 14628738 — intervention group
Group type: COMPARATOR
Intervention: EuroCollins solution
Number of subjects: 0
Study 14628738 — intervention group
Group type: EXPERIMENTAL
Intervention: University of Wisconsin (UW) solution
Number of subjects: 0
Study 4030486 — intervention group
Group type: EXPERIMENTAL
Intervention: UV-filtering posterior chamber intraocular lens (IOL)
Number of subjects: 0
Study 4030486 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary capsulotomy during extracapsular cataract surgery
Number of subjects: 0
Study 4030486 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronidase added to retrobulbar anesthetic injection
Number of subjects: 0
Study 4030486 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical indomethacin before surgery and for nine months postoperatively
Number of subjects: 0
Study 4030486 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study 29083477 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal birch pollen allergen Bet v 1
Number of subjects: 0